|
KMID : 0380020200350020105
|
|
Korean Journal of Biotechnology and Bioengineering
2020 Volume.35 No. 2 p.105 ~ p.119
|
|
|
Therapeutic Antibodies for the Treatment of Cancer: Cancer Immunotherapy
|
|
Yu Han-Jin
Hong Se-Young
Kwon Mi-Ji
Lee Ji-Hyeon
Park Hee-Ho
Lim Kwang-Suk
|
|
|
Abstract
|
|
|
|
Recently, biopharmaceutical drugs take a big part in the pharmaceutical market with the development of genetic engineering. Therapeutic antibodies, one of the representative biopharmaceuticals, have strong therapeutic efficacy in various diseases such as autoimmune disease, rheumatism and cancer. Antibodies are widely used as targeted delivery systems, diagnostics and therapeutics because of their high specific recognition ability. In addition, the market for therapeutic antibodies is expanding further with the development of new biologic drugs such as biosimilar and biobetter. In particular, cancer immunotherapy has shown excellent efficacy for the treatment of cancer by regulating the immune response. In recent years, antibody-drug conjugates (ADCs), immune checkpoint inhibitors and therapeutic antibodies have been developed by many researchers and pharmaceutical companies and approved by U.S. food and drug administration as a potential strategy for the treatment of cancer. Although cancer immunotherapy has a strong therapeutic efficacy, there are still limitations to overcome such as for the treatment of solid tumor, immunogenicity and resistance. To solve these problems, new biomarkers, bispecific antibodies and combinatorial therapy with chemotherapy are being investigated. In this review, we describe the mechanism of immune response with respect to antibody therapeutics, characteristics of target cancers and discuss the potentials of cancer immunotherapy.
|
|
|
KEYWORD
|
|
|
cancer immunotherapy, antibody therapeutics, antibody engineering, antibody-drug conjugate, immune checkpoint blockade
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|